Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kintor Pharmaceutical's Enterprise Value is HK$351.34 Mil.
Kintor Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,158.50 Mil. Therefore, Kintor Pharmaceutical's EV-to-EBIT ratio for today is -0.30.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kintor Pharmaceutical's Enterprise Value is HK$351.34 Mil.
Kintor Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,148.47 Mil. Therefore, Kintor Pharmaceutical's EV-to-EBITDA ratio for today is -0.31.
Kintor Pharmaceutical Enterprise Value Historical Data
The historical data trend for Kintor Pharmaceutical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintor Pharmaceutical's Enterprise Value
For the Biotechnology subindustry, Kintor Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Enterprise Value falls into.
Kintor Pharmaceutical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kintor Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (HKSE:09939) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kintor Pharmaceutical's current Enterprise Value is HK$351.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,158.50 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kintor Pharmaceutical's EV-to-EBITDA for today is:
Kintor Pharmaceutical's current Enterprise Value is HK$351.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,148.47 Mil.
Kintor Pharmaceutical's current Enterprise Value is HK$351.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical Enterprise Value Related Terms
Thank you for viewing the detailed overview of Kintor Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintor Pharmaceutical (HKSE:09939) Business Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09939 has been successfully added to your 